Retatrutide injection

Retatrutide is an injectable weight-loss and diabetes drug developed by Eli Lilly, currently in Phase 3 clinical trials. It is not yet approved/licensed by any regulatory bodies in UK or World wide.

Retatrutide is a new triple-agonist weight-loss injection that is still undergoing clinical trials and development. Early trials show it may lead to an average weight loss of 24.2% over 48 weeks—the highest seen so far among obesity treatments.

Any medication being offered as Retatrutide online should not be used as these are imitation medications and not licensed. These products should be avoided entirely to ensure patient safety.

As it is still being studied, it is not yet licensed or available to buy in the UK or anywhere else around the world. You can sign up for updates by filling out the form above.

Retatrutide at a glance

Item	Summary content
Medicine name	Retatrutide (sometimes called a “triple G” or triple agonist weight loss injection). Triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors
Status at Quick Meds	Not available yet. Sign up for an email notification for when it is licensed and supplied through our registered UK pharmacy.
Regulatory status	Still in clinical development. Not approved by the MHRA and no Clinical guidance from NICE, so it cannot legally be prescribed or sold in the UK.
How it works	A once weekly injection being studied as a triple hormone receptor agonist, targeting GLP-1, GIP and glucagon receptors to reduce hunger, slow digestion, support blood sugar control and increase energy use.
How it is taken	Subcutaneous injection (into the fatty layer under the skin) of the abdomen, thigh or upper arm, given once a week in clinical trials.
Who it is being studied for	Adults with obesity, or with overweight and weight related health conditions such as high blood pressure, Type 2 Diabetes, raised Cholesterol or for those under specialist supervision.
Average weight loss seen in trials	In a phase 2 trial, people on the highest dose (12 mg weekly) lost on average around 24.2% of their starting body weight after 48 weeks, more than the placebo group. This is early research and no formal licensed guidance has been provided as of yet.
Common side effects so far	Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation and abdominal pain have been reported in trials. However, as of yet the long term safety profile is still being studied.
Illegal “peptide” products	Any version of Retatrutide sold now as a “research peptide” or unlicensed jab in the UK is illegal and not the genuine, trialled medicine. Taking 'fake' medications can put the individual at risk of injecting contaminated chemicals into their body with potential incorrect dosing, whilst not having safe prescribing checks.
Licensed alternatives available now	Quick Meds currently offers a range of licensed weight loss treatments, which includes: Mounjaro, Wegovy, Orlistat and Saxenda.

At present, Retatrutide is not available in the UK or anywhere in the world. It is still in early clinical trials. Once it gains approval by the MHRA (medicines healthcare products regulatory agency), Quick Meds is expecting to offer this to all eligible patients.

We currently offer a range of licensed weight loss treatments, including Wegovy, Mounjaro, Nevolat and Orlistat.

Sign up for retatrutide updates from Quick Meds

Retatrutide is still being studied, it is not yet licensed or available to buy. You can sign up for updates by filling out the form above.

You will get email updates as new information is released with regards to updates for Retatrutide.

Signing up does not provide priority status. All patient's will still be required to undergo appropriate clinical checks for safety and suitability once and if the medication is licensed in UK.

For data protection and GDPR purposes all emails will be kept protected as per Quick Meds privacy & data protection polices.

What is retatrutide?

A new triple hormone weight loss injection in development

Retatrutide is a once-weekly weight loss injection that targets three hormones: GLP-1, GIP, and glucagon.

According to Eli Lilly clinical data, this “triple G” mechanism sets Retatrutide apart from Wegovy, which targets one hormone, and Mounjaro, which targets two. Retatrutide is the first triple-agonist therapy in development for obesity, combining the actions of three key metabolic hormones.

This “triple G” effect is what makes Retatrutide one of the most advanced treatments in development. In clinical trials, it led to greater weight loss than any currently available medication.

How does retatrutide work in the body?

• Retatrutide helps with weight loss by mimicking hormones that reduce hunger, slow digestion, and increase energy use.

• GLP-1 stimulates the release of insulin, slows your digestion, and helps suppress your appetite.

• GIP enhances insulin release and may work to prevent fat buildup.

• GCG may increase the amount of energy your body uses while helping to burn fat.

This triple mechanism helps reduce hunger, improve insulin sensitivity, and may increase the number of calories your body burns, all of which support sustained and meaningful weight loss.

Current research is still ongoing and we are still learning exactly how this triple action translates into long term benefits and risks.

Is Retatrutide available in the UK yet?

• Retatrutide is not yet licensed in the UK or any other country and therefore cannot be prescribed or supplied at this time.

Phase 3 trials have shown positive results for weight loss and blood sugar control. Eli Lilly has started the process to submit Retatrutide for regulatory approval with a possible UK launch around 2026, though the timeline may change.

Quick Meds is expecting to offer this to all eligible patients once it has attained full regulatory approval. This means once the MHRA has licensed the treatment and when NICE has issued clear guidance on safe prescribing.

What do the retatrutide clinical trials tell us so far?

Overview of key clinical trials & how much weight did people lose?

How Retatrutide compares with other weight loss injections?

Retatrutide is currently being investigated in Phase 3 clinical trial for obesity in patients who have other co-morbidities (health conditions/disease states related to weight). The trial is due to end in May 2026.

We can review the now completed phase 2 research to get an idea of Retatrutide weight loss results. Here, people on the highest dose of the medicine lost 24.2% of their starting weight after 48 weeks. What’s more, 26% of participants lost at least 30% of their initial weight.

For comparison with other weight loss injectable products:

• Mounjaro: 20.5% mean weight loss after 48 weeks (estimated from 72 week data)

• Wegovy (2.4 mg): 15% mean weight loss after 48 weeks (estimated from 72 week data)

• Wegovy (7.2 mg): 18% mean weight loss after 48 weeks (estimated from 72 week data)

Therefore, Retatrutide currently shows the most significant weight-loss potential of any GLP-1–based drug studied to date.

These results are under strict clinical testing and parameters and that real world weight loss potential will differ for each individual patient.

Effects on blood sugar, blood pressure and cholesterol

Clinical trial data suggests several benefits of taking the treatment for obesity or type 2 diabetes:

1. Meaningful weight loss - participants taking higher doses in trials lost a significant amount of their starting body weight on average.

2. Improved blood sugar levels- participants with diabetes showed more controlled blood sugar levels and insulin sensitivity.

3. Cardiovascular benefits - Retatrutide showed benefit in the management of the following conditions; high blood pressure, high cholesterol and improving heart health.

''Treatment with Retatrutide was associated with improvements in cardiometabolic measures (exploratory end points) including systolic and diastolic blood pressure and levels of glycated hemoglobin, fasting glucose, insulin, and lipids''.

Long term data is still needed to understand cardiovascular and kidney outcomes to ensure safe prescribing.

How is retatrutide given and what is the dosing schedule?

How often is Retatrutide injected?

Retatrutide is designed to be taken as a once weekly injection, taken roughly at the same time every week. Patients should never change the dose, stop or restart treatment without medical advice.

The final dosing schedule may change once the medicine is licensed but it is expected to follow the pattern based on trials data:

• Start at a low dose, which is gradually increased, similar to how other treatments are prescribed.

• Switching to a maintenance dose once your body has adjusted.

Doses used in clinical trials

The doses studied in the Clinical trial, against placebo, was; 1mg, 4mg, 8mg an 12mg. Patient's started on a lower dose and then built up gradually https://quickmeds.co.uk/online-clinic/weight-loss/ to reduce side effects.

The final licensed dose options, if approved, may differ from the trial doses.

Why dosing must be personalised and supervised

Only a qualified prescriber will decide the correct/safe dose and schedule, based on medical history, other medicines, side effects and progress.

Strict caution must be taken against doses seen on social media, in forums or from unregulated “research peptide” sellers. This is to ensure safe prescribing, in-line with regulation protocols & licensed dosing.

Potential benefits of Retatrutide (if future trials confirm safety)

Weight loss and weight related health conditions

Clinical trial data suggests several benefits of taking the treatment for obesity or type 2 diabetes:

1. Meaningful weight loss - participants taking higher doses in trials lost a significant amount of their starting body weight on average.

2. Improved blood sugar levels- participants with diabetes showed more controlled blood sugar levels and insulin sensitivity.

3. Cardiovascular benefits - Retatrutide showed benefit in the management of the following conditions; high blood pressure, high cholesterol and improving heart health.

''Treatment with Retatrutide was associated with improvements in cardiometabolic measures (exploratory end points) including systolic and diastolic blood pressure and levels of glycated hemoglobin, fasting glucose, insulin, and lipids''.

Additional benefits can be taken from weight loss studies, which can include benefits to overall health and sleep apnoea to name a few.

Long term data is still needed to understand cardiovascular and kidney outcomes to ensure safe prescribing.

Be aware that the benefits are not guaranteed for everyone and depend on sticking to treatment regimen alongside active lifestyle changes.

Side effects and safety – what we know so far

Commonly reported side effects

Serious and longer term safety questions

As with all GLP-1- GIP based medications the side effect profile remains the same and increases in likelihood as the dose increases. This was found more significantly at the 8mg and 12 mg version of treatment.

"The most frequently reported adverse events were gastrointestinal (nausea, diarrhoea, vomiting, and constipation) and occurred more frequently with Retatrutide than with placebo''.

These side effects , when reported, was only during the dose initiation stage and was found to stabilise as time went on.

The full extent of the safety profile, including long-term cautions and rare side effects, for this medication has not yet been fully understood and will be reviewed prior to being licensed in the UK and abroad.

Who might be at higher risk of problems?

Individuals who may be at higher risk with GLP-1-GIP/incretin based injections generally include those people with a history of pancreatitis, active gallstones, severe gut disease or certain endocrine conditions, based on class effects of GLP-1 and similar drugs.

Anyone with a complex medical history should first speak to their GP or specialist before considering future treatments like Retatrutide.

Retatrutide, “research peptides” and illegal sales in the UK

Strict caution must be taken against doses seen on social media, in forums or from unregulated “research peptide” sellers. This is to ensure safe prescribing, in-line with regulation protocols & licensed dosing.

Risks of unlicensed “peptide” versions of retatrutide

There are reports of some websites, beauty salons and social media sellers who are marketing unlicensed “Retatrutide” vials or pens as “research peptides” or “skinny jabs”. This is illegal and unsafe.

• Some of key risks involved with using 'fake' Retatrutide or any similar GLP-1-GIP or similar weight loss medications:

• No quality control or batch testing

• Possible contamination or incorrect active ingredient

• Doses that are too strong or too weak

• No proper medical screening, monitoring or follow up procedures

Quick Meds will never supply unlicensed versions or “research peptides” and will only dispense MHRA regulated medicines.

How Quick Meds will support you if retatrutide is approved

Safe online assessment and prescribing

As a GPhC registered Pharmacy, here at Quick Meds, we pride ourselves on providing the highest level of care with your safety as our priority. We already provide licensed weight loss treatments safely and the same high standards will apply to Retatrutide when it becomes available.

• We use UK-registered Prescribers and pharmacists, with experience in GLP-1 treatments

• We provide clear, evidence-based patient-friendly information, written and reviewed by healthcare professionals

• Discreet delivery across the UK as soon as by the next working day

• Ongoing aftercare and easy access to advice whenever you need it.

Our treatment package includes an online consultation through: a detailed questionnaire, reviewed by the clinical team, checks of weight, BMI, medical history and current medicines. This will then be discussed via a telephone consultation and provision of a information package for the patient to review prior to initiation.

Our Clinical staff of Pharmacists and related team members as well as qualified Prescribers, all of whom are registered in the UK, are here to support your weight loss journey and ensure safe and appropriate treatment.

Ongoing support during your weight loss journey

Quick Meds will also allow patients to engage in follow up reviews, dose checks, side effect monitoring and the option to switch to alternative treatments if Retatrutide is not suitable.

We also provide access to written advice about nutrition, physical activity and long term weight maintenance.

Licensed alternatives available at Quick Meds today

Current GLP-1 and GIP based weight loss injections

Currently the licensed options that Quick Meds supplies for weight loss treatment include: Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda & Nevolat) and Orlistat.

Other licensed weight loss medications

Retatrutide, although still undergoing clinical trials, will likely have once weekly injection dosing as similar to Mounjaro and Wegovy. These medications are already licensed for use in the UK for weight loss treatment.

All medicines offered by Quick Meds are prescribed based on individual needs and eligibility criteria so as to ensure safe and appropriate treatment.

Lifestyle changes alongside any medication

Here at Quick Meds our emphasis for stable and long-lasting weight loss is through lifestyle adjustment. A proactive and consistent change in lifestyle habits will not only optimise weight loss, in conjunction or without with Medicinal therapy. This holistic change will enable patient's to more easily taper off treatment and maintain their weight loss.

Our Clinical team will offer written and verbal tailored lifestyle advice, which can highlight the importance of; diet, physical activity, sleep and psychological support, regardless of which medication is used.

Key takeaways: Retatrutide in simple terms

• Retatrutide key points:

• Retatrutide is a promising but still experimental weekly injection for weight loss and metabolic health.

• It has shown very high average weight loss in phase 2 trials, but longer term data and phase 3 results are still needed.

• It is not yet licensed anywhere, so you cannot legally buy genuine Retatrutide in the UK.

• Unlicensed “peptide” products are risky and should be avoided.

• There are safe, licensed weight loss treatments available now through Quick Meds, with clinical support at every step.

FAQs